Top

Published in:

01-06-2013 | Pediatric Infectious Diseases (I Brook, Section Editor)

Probiotics and Prebiotics in Infants and Children

Authors: Y. Vandenplas, E. De Greef, T. Devreker, G. Veereman-Wauters, B. Hauser

Published in: Current Infectious Disease Reports | Issue 3/2013

Abstract

Probiotics and prebiotics have a major influence on gastrointestinal flora composition. This review analyses the relationship between this change in flora composition and health benefits in children. Literature databases were searched for relevant articles. Despite exhaustive research on the subject in different indications, such as prevention and treatment of acute gastroenteritis, antibiotic associated diarrhea (AAD), traveler's diarrhea, inflammatory bowel disease, irritable bowel syndrome, Helicobacter pylori, necrotizing enterocolitis, constipation, allergy and atopic dermatitis, colic and extraintestinal infections, reports of clear benefits for the use of prebiotics and probiotics in pediatric disorders remain scarce. The best evidence has been provided for the use of probiotics in acute gastroenteritis and in prevention of AAD. However, AAD in children is in general mild, and only seldom necessitates additional interventions. Overall, the duration of acute infectious diarrhea is reduced by approximately 24 hours. Evidence for clinically relevant benefit in all other indications (inflammatory bowel disease, irritable bowel syndrome, constipation, allergy) is weak to nonexistent. Selected probiotic strains given during late pregnancy and early infancy decrease atopic dermatitis. Adverse effects have very seldom been reported. Since the risk seems minimal to nonexistent, prebiotics and probiotics may be helpful in the prevention and treatment of some disorders in children, although the evidence for benefit is limited. The best evidence has been accumulated for some lactobacilli strains and for Saccharomyces boulardii in the reduction of the duration of acute diarrhea due to gastroenteritis and prevention of AAD.

Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129:950–60.PubMedCrossRef

•• Reid G. Microbiology: Categorize probiotics to speed research. Nature. 2012;485:446. Classifies different probiotic products and proposes minimal requirements for claims.PubMedCrossRef

Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.PubMedCrossRef

Vandenplas Y. Identification of probiotics by specific strain name. Aliment Pharmacol Ther. 2012;35:860.CrossRef

Bicer S, Sahin GT, Koncay B, et al. Incidence assessment of rotavirus and adenovirus associated acute gastroenteritis cases in early childhood. Infez Med. 2011;19:113–9.PubMed

Muhsen K, Shulman L, Rubinstein U, et al. TAU-HCLV Rota Study Group. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007–2008. J Infect Dis. 2009;200 Suppl 1:S254–63.PubMedCrossRef

Goldman AS. Evolution of immune functions of the mammary gland and protection of the infant. Breastfeed Med. 2012;7:132–42.PubMedCrossRef

Martín V, Maldonado-Barragán A, Moles L, et al. Sharing of bacterial strains between breast milk and infant feces. J Hum Lact. 2012;28:36–44.PubMedCrossRef

Totten SM, Zivkovic AM, Wu S, et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012;11:6124–33.PubMed

10.

Agustina R, Kok FJ, van de Rest O, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012;129:e1155–64.PubMedCrossRef

11.

Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–53.PubMedCrossRef

12.

Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2012;161:40–3.PubMedCrossRef

13.

Gil-Campos M, López MÁ, Rodriguez-Benítez MV, et al. Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1–6 months of age: a randomized controlled trial. Pharmacol Res. 2012;65:231–8.PubMedCrossRef

14.

• Braegger C, Chmielewska A, Decsi T, et al. ESPGHAN Committee on Nutrition. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238–50. An ESPGHAN position paper on (the poor evidence of benefit of) pre- and probiotics added to infant formula.PubMedCrossRef

15.

Thomas DW, Greer FR. Clinical report: probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–31.PubMedCrossRef

16.

Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr. 2009;28:156–61.PubMedCrossRef

17.

• Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13:17–26. For the first time, the socio-economic impact of decreasing the duration of diarrhea with 24 hours is recognized as important.PubMedCrossRef

18.

Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea – a double-blind study. Aliment Pharmacol Ther. 2012;36:363–9.PubMedCrossRef

19.

Sarker SA, Sultana S, Fuchs GJ, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics. 2005;116:e221–8.PubMedCrossRef

20.

Muñoz JA, Chenoll E, Casinos B, et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol. 2011;77:8775–83.PubMedCrossRef

21.

Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79:478–82.PubMedCrossRef

22.

Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11, CD003048.PubMed

23.

Churgay CA, Aftab Z. Gastroenteritis in children: Part II. Prevention and management. Am Fam Physician. 2012;85:1066–70.PubMed

24.

Vandenplas Y. De Hert S; Probiotical study group. Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save. Benef Microbes. 2012;3:189–94.PubMedCrossRef

25.

Hoekstra JH, Szajewska H, Zikri MA, et al. Oral rehydration solution containing a mixture of non-digestible carbohydrates in the treatment of acute diarrhea: a multicenter randomized placebo controlled study on behalf of the ESPGHAN working group on intestinal infections. J Pediatr Gastroenterol Nutr. 2004;39:239–45.PubMedCrossRef

26.

Passariello A, Terrin G, De Marco G, et al. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial. J Pediatr. 2011;158:288–92.PubMedCrossRef

27.

Passariello A, Terrin G, Cecere G, et al. Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea. Aliment Pharmacol Ther. 2012;35:782–8.PubMedCrossRef

28.

Vandenplas Y. De Hert SG; PROBIOTICAL-study group. Randomised clinical trial: the synbiotic food supplement Probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther. 2011;34:862–7.PubMedCrossRef

29.

Pieścik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37:289–303.PubMedCrossRef

30.

Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.PubMedCrossRef

31.

Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355–69.PubMedCrossRef

32.

Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–82.PubMedCrossRef

33.

•• Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. An excellent meta-analysis showing efficacy of selected probiotic strains in the prevention of antibiotic-associated diarrhea.PubMed

34.

Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107:922–31.PubMedCrossRef

35.

Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41:763–79.PubMedCrossRef

36.

Cremonini F, Videlock EJ. Probiotics are associated with a decreased risk of antibiotic-associated diarrhoea. Evid Based Med. 2013;18:71–2.PubMedCrossRef

37.

ESPGHAN Working Group on Probiotics and Prebiotics, Szajewska H, Weizman Z, Abu-Zekry M, et al. Inulin and fructo-oligosaccharides for the prevention of antibiotic-associated diarrhea in children: report by the ESPGHAN Working Group on Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2012;54:828–9.PubMedCrossRef

38.

•• Vanhee LM, Goemé F, Nelis HJ, Coenye T. Quality control of fifteen probiotic products containing Saccharomyces boulardii. J Appl Microbiol. 2010;109:1745–52. A nice study showing that what matters are commercial products, not strains. Clinical studies should be performed with the commercial product.PubMed

39.

McFarland LV. Probiotics and diarrhea. Ann Nutr Metab. 2010;57(Suppl):10–1.PubMedCrossRef

40.

DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16:149–60.PubMedCrossRef

41.

Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler's diarrhea. Infect Dis Clin North Am. 2012;26:691–706.PubMedCrossRef

42.

Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35:327–34.PubMedCrossRef

43.

Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.PubMedCrossRef

44.

Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:184–9.PubMedCrossRef

45.

Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRef

46.

• Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:821–42. Although relating mainly to adults, this overview shows the (lack of ) evidence of probiotics in inflammatory bowel disease.PubMedCrossRef

47.

Park KT, Perez F, Tsai R, et al. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:489–96.PubMed

48.

Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;1, CD003019.PubMed

49.

Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126:e1445–52.PubMedCrossRef

50.

Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–10.PubMedCrossRef

51.

Vivatvakin B, Mahayosnond A, Theamboonlers A, et al. Effect of a whey-predominant starter formula containing LCPUFAs and oligosaccharides (FOS/GOS) on gastrointestinal comfort in infants. Asia Pac J Clin Nutr. 2010;19:473–80.PubMed

52.

Khoshoo V, Sun SS, Storm H. Tolerance of an enteral formula with insoluble and prebiotic fiber in children with compromised gastrointestinal function. J Am Diet Assoc. 2010;110:1728–33.PubMedCrossRef

53.

Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15:79–87.PubMedCrossRef

54.

Kindermann A, Lopes AI. Helicobacter pylori infection in pediatrics. Helicobacter. 2009;14 Suppl 1:52–7.PubMedCrossRef

55.

Lionetti E, Francavilla R, Castellazzi AM, et al. Probiotics and helicobacter pylori infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):69–76.

56.

Lin WH, Lin CK, Sheu SJ, et al. Antagonistic activity of spent culture supernatants of lactic acid bacteria against Helicobacter pylori growth and infection in human gastric epithelial AGS cells. J Food Sci. 2009;74:225–30.CrossRef

57.

Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17:297–304.PubMedCrossRef

58.

Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–79.PubMedCrossRef

59.

• Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28:608–14. Many probiotics increase the eradication efficacy of standard treatment by about 10 %.PubMedCrossRef

60.

Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960–6.PubMedCrossRef

61.

Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197–202.PubMedCrossRef

62.

Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;3, CD005496.PubMed

63.

Downard CD, Renaud E, St Peter SD, et al. 2012 American Pediatric Surgical Association Outcomes Clinical Trials Committee. Treatment of necrotizing enterocolitis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47:2111–22.PubMedCrossRef

64.

•• Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr. 2012;31:6–15. The efficacy of probiotics on the prevention of NEC is put in its right perspective.PubMedCrossRef

65.

•• Janvier A, Lantos J, Barrington K. The politics of probiotics: probiotics, necrotizing enterocolitis, and the ethics of neonatal research. Acta Paediatr. 2013;102:116–8. These authors have a different opinion from Mihatsch et al. The debate "probiotic or not" in the prevention of necrotizing enterocolitis is open.PubMedCrossRef

66.

Szajewska H. Probiotics and prebiotics in preterm infants: where are we? Where are we going? Early Hum Dev. 2010;86 Suppl 1:81–6.PubMedCrossRef

67.

Tabbers MM, de Milliano I, Roseboom MG, Benninga MA. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J. 2011;10:19.PubMedCrossRef

68.

Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157:598–602.PubMedCrossRef

69.

Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol. 2011;17:3916–21.PubMedCrossRef

70.

Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011;127:e1392–9.PubMedCrossRef

71.

Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011;128:753–61.PubMedCrossRef

72.

Schouten B, Van Esch BC, Kormelink TG, et al. Non-digestible oligosaccharides reduce immunoglobulin free light-chain concentrations in infants at risk for allergy. Pediatr Allergy Immunol. 2011;22:537–42.PubMedCrossRef

73.

Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;4:CD006475.PubMed

74.

Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol. 2010;163:616–23.PubMedCrossRef

75.

•• Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr. 2012;107:1–6. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMedCrossRef

76.

Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42:1071–9.PubMedCrossRef

77.

Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402–14.PubMedCrossRef

78.

Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 2. Disease prevention and treatment. Clin Exp Dermatol. 2010;35:223–7.PubMedCrossRef

79.

van der Aa LB, Lutter R, Heymans HS, et al. Synbad Study Group. No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis. Clin Exp Allergy. 2012;42:531–9.PubMedCrossRef

80.

van der Aa LB, van Aalderen WM, Heymans HS, et al. Synbad Study Group. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy. 2011;66:170–7.PubMedCrossRef

81.

Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol. 2012;166:129–36.PubMedCrossRef

82.

Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2012;23:667–73.PubMedCrossRef

83.

Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012;42:112–22.PubMedCrossRef

84.

•• Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMed

85.

Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–33.PubMedCrossRef

86.

Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–62.PubMedCrossRef

87.

Dupont C, Rivero M, Grillon C, et al. Alpha-lactalbumin-enriched and probiotic-supplemented infant formula in infants with colic: growth and gastrointestinal tolerance. Eur J Clin Nutr. 2010;64:765–7.PubMedCrossRef

88.

Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–7.PubMedCrossRef

89.

Picaud JC, Chapalain V, Paineau D, et al. Incidence of infectious diseases in infants fed follow-on formula containing synbiotics: an observational study. Acta Paediatr. 2010;99:1695–700.PubMedCrossRef

90.

Maldonado J, Cañabate F, Sempere L, et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54:55–61.PubMedCrossRef

91.

Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122:8–12.PubMedCrossRef

92.

van Stuijvenberg M, Eisses AM, Grüber C, et al. Do prebiotics reduce the number of fever episodes in healthy children in their first year of life: a randomised controlled trial. Br J Nutr. 2011;106:1740–8.PubMedCrossRef

93.

Popova M, Molimard P, Courau S, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol. 2012;113:1305–18.PubMedCrossRef

94.

Taipale T, Pienihäkkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409–16.PubMedCrossRef

95.

Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101:1722–6.PubMedCrossRef

96.

Skovbjerg S, Roos K, Holm SE, et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child. 2009;94:92–8.PubMedCrossRef

97.

Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children – a double-blind, placebo-controlled randomised study. Clin Nutr. 2007;26:314–21.PubMedCrossRef

98.

Stecksén-Blicks C, Sjöström I, Twetman S. Effect of long-term consumption of milk supplemented with probiotic lactobacilli and fluoride on dental caries and general health in preschool children: a cluster-randomized study. Caries Res. 2009;43:374–81.PubMedCrossRef

99.

Niittynen L, Pitkäranta A, Korpela R. Probiotics and otitis media in children. Int J Pediatr Otorhinolaryngol. 2012;76:465–70.PubMedCrossRef

100.

Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediat Infect Dis J. 2012;31:859–62.CrossRef

101.

Sazawal S, Dhingra U, Hiremath G, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010;5:e12164.PubMedCrossRef

102.

Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.PubMed

103.

Salvini FJ, Riva E, Salvatici E, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. J Nutr. 2011;141:1335–9.PubMedCrossRef

104.

Stam J, van Stuijvenberg M, Garssen J, et al. A mixture of three prebiotics does not affect vaccine specific antibody responses in healthy term infants in the first year of life. Vaccine. 2011;29:7766–72.PubMedCrossRef

105.

Hong P, Ninonuevo MR, Lee B, et al. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101:482–6.PubMedCrossRef

106.

Sanz-Penella JM, Frontela C, Ros G, et al. Application of bifidobacterial phytases in infant cereals: effect on phytate contents and mineral dialyzability. J Agric Food Chem. 2012;60:11787–892.PubMedCrossRef

107.

Capozzi V, Russo P, Dueñas MT, et al. Lactic acid bacteria producing B-group vitamins: a great potential for functional cereals products. Appl Microbiol Biotechnol. 2012;96:1383–94.PubMedCrossRef

108.

• Shanahan F. A commentary on the safety of probiotics. Gastroenterol Clin North Am. 2012;41:869–76. Are probiotics really safe?.PubMedCrossRef

109.

Allen SJ, Jordan S, Storey M, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr. 2010;140:483–8.PubMedCrossRef

110.

Martín-Muñoz MF, Fortuni M, Caminoa M, et al. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. Pediatr Allergy Immunol. 2012;23:778–84.PubMedCrossRef

111.

•• Dai M, Lu J, Wang Y, et al. In vitro development and transfer of resistance to chlortetracycline in Bacillus subtilis. J Microbiol. 2012;50:807–12. The danger of transfer of plasmid resistance with some probiotic strains.PubMedCrossRef

112.

Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16–20.PubMedCrossRef

113.

Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis. 2010;16:1661–5.PubMedCrossRef

114.

Manzoni P, De Luca D, Stronati M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81–8.PubMedCrossRef

115.

Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediatr Infect Dis J. 2012;31:856–62.CrossRef

116.

Mugambi MN, Musekiwa A, Lombard M, et al. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J. 2012;11:81.PubMedCrossRef

Title: Probiotics and Prebiotics in Infants and Children
Authors: Y. Vandenplas
E. De Greef
T. Devreker
G. Veereman-Wauters
B. Hauser
Publication date: 01-06-2013
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 3/2013
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-013-0334-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Antifungal Agents in Current Pediatric Practice

Fusobacterial Infections in Children

Long-Term Sequelae of Childhood Bacterial Meningitis

Rheumatic Fever and Post-Group A Streptococcal Arthritis in Children

Chronic Diarrhea in Travelers

Reducing Central Line Infections in Pediatric and Neonatal Patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials